Imaging Biometrics Ltd
IBAI · Main Market · Health Care · mcap £2.2m · 0.9p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 01 Oct 26 | Strengthening pipeline prominent US institutions
Q3 2026: strengthened US pipeline with prominent academic medical centres and health systems; two new subscriptions added. |
+11.1% | |
| 15 Sep 26 | Adoption of Advanced Brain Tumor Imaging Platform
Leading regional health system adopts Imaging Biometrics' quantitative neuro-oncology imaging software on annual subscription. |
+22.0% | |
| 28 Aug 26 | US Academic Medical Centre Adopts IB Clinic
Major US academic medical centre adopts IB Clinic software on annual subscription for brain tumour imaging. |
+5.0% | |
| 29 Jul 26 | Results | Half-year Results
H1 2026 revenue grew 6% to £416,270 and company returned to operating profit of £88,678 from prior loss. |
+0.0% |
| 14 Jul 26 | Sub-division
Further to the announcements of 12 May and 3 June, the Company is pleased to confirm that the sub-division has completed with a resulting 246,709,789 ordinary shares of £0.005. |
+0.0% | |
| 09 Jun 26 | Publication of Phase 1 Clinical Trial
Phase 1 trial of oral gallium maltolate in glioblastoma published; safe profile and median survival of 16 months reported. |
−3.1% | |
| 05 Jun 26 | Results | Commercialisation, Phase II Results & Revenue Path
Phase II trial results validate IB Neuro automated biomarker for early response assessment in glioblastoma treatment. |
+16.7% |
| 03 Jun 26 | Routine | Result of AGM | |
| 03 Jun 26 | AGM Statement and Business Update
Imaging Biometrics Limited (LSE: IBAI) is pleased to provide this update to shareholders ahead of its Annual General Meeting being held today. |
+0.0% | |
| 13 May 26 | Amendement To Notice Of Annual General Meeting
The Company notes an error to RNS 12 May 2026 (RNS Number: 0280E), that incorrectly stated that the ordinary shares of £0.01 will be sub-divided into one ordinary share of £0.0005. |
+0.0% | |
| 12 May 26 | Routine | Notice of AGM | |
| 08 May 26 | KIRKSTALL AWARDED BBSRC/NC3Rs GRANT: GLIOBLASTOMA
Kirkstall awarded BBSRC/NC3Rs grant to develop glioblastoma tumour-on-chip model with Nottingham Trent University. |
+0.0% | |
| 30 Apr 26 | Results | Annual Report for the Year Ended 31 December 2025
FY25 revenue rose 5% to £788k; Kirkstall acquisition completed; operating loss widened to £401k. |
+0.0% |
| 19 Feb 26 | Board change | Board Appointment
John Charles Richardson appointed as Non-Executive Director effective 1 March 2026. |
−8.2% |
| 11 Feb 26 | Update and IB Nimble Webinar – 27 February 2026
Imaging Biometrics Limited ('IBAI') comprises two subsidiary businesses, Imaging Biometrics LLC and Kirkstall Limited. |
+5.3% | |
| 16 Jan 26 | Strategic Direction Fueling Organic Growth
IBAI discontinues Phase 2 gallium maltolate trial, refocusing on imaging solutions for near-term commercial objectives. |
−35.3% | |
| 10 Dec 25 | Expansion Global Distribution Agreement with GE
Imaging Biometrics expands GE HealthCare distribution agreement to include FTB Express Maps and QSMetric software. |
+11.1% | |
| 26 Nov 25 | Release of Next-Generation IB Clinic
Imaging Biometrics releases next-generation IB Clinic with enhanced automation, scalability and workflow integration. |
+8.1% | |
| 24 Nov 25 | Board change | Directorate Change
Dr Al Musella stepping down from Board effective 31 December 2025, becoming Medical Advisor to subsidiary. |
+0.0% |
| 13 Nov 25 | Fractional Tumor Burden Mapping Enhances GBM Trial
Imaging Biometrics' Fractional Tumor Burden mapping technology adopted in glioblastoma clinical trial at MD Anderson Cancer Center. |
+11.1% | |
| 10 Nov 25 | IB Announces Completion of Phase 1 Trial of GaM
Phase 1 trial of oral gallium maltolate for glioblastoma completed successfully with favourable safety profile. |
+60.0% | |
| 16 Oct 25 | Further Re: Purchase of interest in Kirkstall Ltd
IBAI acquires interest in Kirkstall Limited; Truetide writes off £220,853.67 in loans to Kirkstall. |
+0.0% | |
| 14 Oct 25 | Purchase of Kirkstall and CLN - Correction
Correction to conversion price of convertible loan notes issued to Truetide plc in Kirkstall and CLN acquisition. |
−16.7% | |
| 14 Oct 25 | Purchase of Kirkstall and CLN with Truetide plc
IBAI acquires 86.11% of Kirkstall Limited for £170,000 with option to take full ownership via drag-along. |
−16.7% |
Company filings. Not investment advice.